TherapeuticsMD Inc. (TXMD) stock recently traded in the premarket at $1.57 which is an 18.94% rise. TXMD’s stock closed at $1.32 which is the same price to its prior session close thus a 0.00% change. The number of shares that exchanged hands in the day was 6.57 million. However, this was lower than the average daily volume of 17.1 million shares within the past 50 days. The volume in the past week was down by -1.49%. TXMD stock has risen by 47.67% in the last 12 months but shed -17.50%. In the last 3 months, it then gained 2.33%. Furthermore, the company’s current market share values at $493.52 million and its outstanding shares stood at 286.69 million.
The recent positive movement of TXMD stock in the recent pre-market trading session has come adjacent to the press release by the Company announcing approval of its Hormone Replacement Therapy (HRT)
TherapeuticsMD healthcare provides special care for women
TherapeuticsMD, Inc. is a healthcare company which is focused towards the production of novel and unique products. These healthcare products are made specifically for women and innovation comes through the design and accordance with the unmet needs/challenges of women. The company looks at various experiences and stages of a woman’s life to keep in mind while designing these products especially for menopause, family planning and reproductive health.
Approval of HRT capsule, BIJUVA® in UK and BIJUVE®in Belgium.
TherapeuticsMDInc (TXMD) along with its collaborating partner Theramex announced the approval of BIJUVE® Capsules in the United Kingdom and under the trade name BIJUVA® in Belgium. Theramex is a global specialty pharmaceutical company and like TXMD stock it is dedicated to women’s health. Its vision is to be a lifetime partner for women and has a portfolio of contraceptive, fertility, menopause, and osteoporosis related products covered under established brand names.
United Kingdom and Belgium are not the first countries where the Hormone Replacement Therapy has been released; USA had BIJUVA made commercially available in April 2019, while Canada and Israel have these commercially available as well. However BIJUVA is Europe’s first and only oral HRT with bio-identical hormones; specifically Estradiol and micronized Progesterone made available.
Theramex signed an exclusive licensing and supply agreement with TherapeuticsMD Inc. in June 2019, to make BIJUVA available outside of these countries, especially in the European market. This agreement states Theramex paying TherapeuticsMD, certain royalties and milestone fees based upon aggregate net sales.
The approval in European countries is a major positive move for TXMD stock
The process of regulatory approval was a decentralized procedure that took place in February and afterwards each country has its own terms and conditions for medical approval. The approval for other significant EU countries will take place shorty, as expected by Theramex. It is possible to see a positive trend of TXMD stock maintain for longer period if commercial availability and approvals come further down the year.